-
Natrapharm was established by Mr. Rudi T. Runes.
Natrapharm, Inc. was established by Mr. Rudi T. Runes in November 1990 with products licensed from the newly-formed Rhone-Poulenc Rorer where he served as president of Rhone-Poulenc Natterman before its merger with Rorer. It was during his tenure that Natterman (Phils) became one of the leading Pharmaceutical companies in the country. source: www.natrapharm.com -
Patriot Pharmaceuticals Corp. was established.
The continued growth of Natrapharm Inc. eventually led to the formation of Patriot Pharmaceuticals Corp. in 1995. Initially conceived as a foray into the generic sector of the pharmaceutical industry, Patriot Pharmaceuticals Corp. evolved to focus primarily on hospital-based products. source: www.natrapharm.com -
Launch of Acalka.
Natra's #6 brand, 185M MAT September 2012 sales Indication:
Acalka is used in the treatment of patients with kidney stones. -
A new building was built.
The group's consistently strong performance in the market paved the way for the construction of its own building which was completed in 1997. source: www.natrapharm.com -
A distribution system was integrated into Natrapharm's internal operations.
Recognizing the need for efficient nationwide delivery structure, a distribution system was integrated into its internal operations in 1999. This approach supported its development needs and became pivotal to group's sustained growth. Since then, the group's product portfolio has expanded from eight to 23 brands, including several market leaders in their therapeutic segments. source: www.natrapharm.com -
Launch of Omacor.
Natra's #8 brand,126M MAT September 2012 sales Indication:
Omacor is used together with diet and exercise to help lower triglyceride levels in the blood. -
An extension building was built.
An extension was added in 2004 to accommodate an upgraded warehouse facility and well-equipped training and education center. The Patriot Building was designed not only as a base for operations, but more importantly, as a symbolic representation of its patriotic pride and commitment to the Filipino culture and values. -
Launch of Natravox.
Natra's #1 brand, 396M MAT September 2012 sales
On it's first year of launch, Natravox rose to #5 in the BLI market with 83M sales ending 2004. Indication:
Natravox is used in the treatment of patients with upper/lower respiratory tract, genito-urinary tract and skin and soft tissue infections -
Launch of Montemax.
Natra's #10 brand, 108M MAT September 2012 sales
On it's first year, Montemax was the #2 brand in the Anti-leuk market (69M). Kastair is at #3 with 47M sales. Indication:
Montemax is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age or older. -
Launch of Vasalat.
Natra's #4 brand, 201M MAT September 2012 sales
On it's 2nd year after launch, Vasalat is already at 142M, #11 in the calcium antagonist plain market. Indication:
Vasalat is used In the management of hypertension and prophylaxis of angina. -
Launch of Zynapse.
Natra's #2 brand, 385M MAT September 2012 sales
On it's 1st year, Zynapse ranked 3rd in the cerebral and peripheral vasothera market with 33M sales. Indication:
Zynapse is a post stroke medication that accelerates the recovery of consciousness and overcoming motor deficit. -
Launch of Platexan.
Natra's #5 brand, 191M MAT September 2012 sales
On it's 2nd year, Platexan ranked #4 in the PAI market with 87M sales. Indication:
Platexan is used to prevent heart attacks and strokes in persons with heart disease (recent heart attack, unstable angina), recent stroke, or blood circulation disease (peripheral vascular disease). It works by blocking certain blood cells called platelets and prevents them from forming harmful blood clots. -
Launch of Zoltax.
Natra's #7 brand, 157M MAT September 2012 sales
On it's 1st year of launch, Zoltax ranked #5 in the 2nd gen cepha market. Indication:
Zoltax is used in the treatment of infections caused by susceptible organisms e.g. bone & joint infections, bronchitis, gonorrhea, meningitis, otitis media. -
Launch of RI/INH/PY/ET (4drug Anti-TB)
Natra's #3 brand, 342M MAT September 2012 sales -
BE Generics was launched.
Natrapharm expanded with a new business unit called BE GENERICS for the handling and distribution of their unibranded drugs (they have a dedicated field force for this unit).
